Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.
about
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseEdaravone guards dopamine neurons in a rotenone model for Parkinson's diseaseThe metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.Role of mGluR4 in acquisition of fear learning and memory.Development of allosteric modulators of GPCRs for treatment of CNS disordersThe external globus pallidus: progress and perspectivesDevelopment and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.Therapeutic potential of metabotropic glutamate receptor modulators.mGluR7 genetics and alcohol: intersection yields clues for addiction.The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.Activation of presynaptic kainate receptors suppresses GABAergic synaptic transmission in the rat globus pallidus.Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex.The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary MicrogliaMetabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence.Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4).Glutamate receptors as therapeutic targets for Parkinson's disease.Metabotropic glutamate receptors: physiology, pharmacology, and disease.mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety.Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's diseaseGroup III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivomGluR4-containing corticostriatal terminals: synaptic interactions with direct and indirect pathway neurons in mice.Selective and interactive effects of D2 receptor antagonism and positive allosteric mGluR4 modulation on waiting impulsivity.Metabotropic glutamate receptors for Parkinson's disease therapy.Electrophysiological and behavioral effects of group III metabotropic glutamate receptors on pallidal neurons in normal and parkinsonian rats.In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease.Unprecedented Control of Selectivity in Nickel-Catalyzed Hydrophosphorylation of Alkynes: Efficient Route to Mono- and Bisphosphonates
P2860
Q24647634-570D73BE-ECB1-40A7-9CCA-176726545701Q26995351-ABB8AD76-AC51-4C2D-90D1-C21F5A8D563CQ27335848-7813CDB1-F2D3-4E70-84FE-6C5568403358Q30458705-32FFF7FB-8E9C-40A2-88AD-98903A28E82CQ30528681-7B7FC6BA-38EF-4D44-8F0C-CD00026902CFQ34373958-0E5A3C0A-D8A6-486F-B260-B7D511F55370Q34512150-CD427C62-E78F-484B-8E7F-49B21FFCF454Q34534818-BD307907-43DB-4FBD-B76E-5A9097017A9AQ35614156-6BC4F116-BED6-49B1-BAC1-A488B963F06EQ35738538-8DA3DC3A-7076-405E-A697-0208B95FF9A4Q35778704-96639F9B-3F23-4D44-AFB4-506DC7BA3CDAQ36197596-8BD401DC-59D4-4EB8-AF68-16C5A9F65142Q36203237-EFFE47BA-EC63-4525-827D-E719E6FFB82EQ36328049-1F7496A2-BD2B-4CD1-AC49-417561AD97FEQ36374309-7D6A0A25-5C8E-4C80-AC93-8F853C7B22C7Q36844773-51477C2E-4212-4B45-A2D3-B0BC2638B90AQ37103693-1FFEE5CB-7DE4-4D5E-9087-D2552BE380A8Q37360436-CE348765-9B4E-4838-9E8C-0F00559EADBCQ37364758-0F6F0FB4-5868-49F4-A463-F50A6A52E326Q37585401-29BE0C84-3B4D-492E-B9B8-1943FE93AB09Q37670222-F5FDCC04-242F-4063-B9A5-291B30734D9CQ37693720-9189EA57-58E4-4515-B3FF-C07C8D735A8DQ37782115-1C10A417-BD07-4E09-A088-2A3E213F24A6Q37999106-BF20A4C5-BA8E-46A8-ACEB-28FF4C88E18AQ38056852-E62A61AA-6895-4075-82AD-09153E1E6C27Q38092819-CC752A16-2E00-4DD7-8473-E5B8B536BD59Q38190016-1993F750-C1DF-4465-BB29-7E4565452432Q38242117-3B57CC95-C593-4E00-96A3-101A6CE4F4DAQ38292149-378FC80A-2C22-481E-A80E-E74B9510BB6EQ39265062-9C13DA56-DFE1-4630-9647-E6172F81B566Q39282544-CEBC5E2A-6407-440E-B8DD-15A22E1DB94FQ39982710-397B77F2-9045-4EC3-96EC-2966D8F7514AQ40035243-9BE121CB-A59A-4981-915A-F3906252A8EDQ41095156-3FE45C73-2F8E-446F-89AE-51334F6DB20FQ41818450-BB760D11-BE57-4D39-AC0F-EAFE6EFAF278Q46771144-1B2B1B10-B3E9-4B32-909A-CCED42A4DBD8Q52665081-91DB29F3-4D54-49F1-A7C0-E6EFCD8113BBQ57346992-F1EEE92E-CF3C-4D44-B95B-E030EC655995
P2860
Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Targeting group III metabotrop ...... models of Parkinson's disease.
@ast
Targeting group III metabotrop ...... models of Parkinson's disease.
@en
Targeting group III metabotrop ...... models of Parkinson's disease.
@nl
type
label
Targeting group III metabotrop ...... models of Parkinson's disease.
@ast
Targeting group III metabotrop ...... models of Parkinson's disease.
@en
Targeting group III metabotrop ...... models of Parkinson's disease.
@nl
prefLabel
Targeting group III metabotrop ...... models of Parkinson's disease.
@ast
Targeting group III metabotrop ...... models of Parkinson's disease.
@en
Targeting group III metabotrop ...... models of Parkinson's disease.
@nl
P2093
P1476
Targeting group III metabotrop ...... models of Parkinson's disease.
@en
P2093
Elvira De Leonibus
Francine Acher
Nathalie Turle-Lorenzo
Sebastien Lopez
P304
P356
10.1523/JNEUROSCI.0299-07.2007
P407
P577
2007-06-01T00:00:00Z